Trends in Preoperative Chemotherapy Utilization for Proximal Pancreatic Cancer: Are We Making Progress?
Authors:
- 4 May 2022
- journal article
- research article
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 26 (8) , 1663-1669
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Trends in utilization of neoadjuvant therapy and short-term outcomes in resected pancreatic cancerThe American Journal of Surgery, 2017
- Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patientsJournal of Surgical Oncology, 2017
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialThe Lancet, 2017
- Neoadjuvant Therapy for Pancreatic CancerAmerican Journal of Clinical Oncology, 2016
- Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic CancerJournal of Gastrointestinal Surgery, 2015
- Postoperative Complications Reduce Adjuvant Chemotherapy Use in Resectable Pancreatic CancerAnnals of Surgery, 2014
- A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas AdenocarcinomaAnnals of Surgery, 2014
- Adjuvant chemotherapy in elderly patients with pancreatic cancerBritish Journal of Cancer, 2013
- Utilization and Determinants of Adjuvant Therapy Among Older Patients Who Receive Curative Surgery for Pancreatic CancerPancreas, 2009
- The Added Value of Multidisciplinary Care for Patients with Pancreatic CancerAnnals of Surgical Oncology, 2008